By VETTAPHARMA reporter: The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for the treatment of moderate to severe acute pain in adults. This approval represents the first drug in a new class of pain management medicines and expands therapeutic options beyond traditional opioid treatments.
Journavx works by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, effectively reducing pain before signals reach the brain. This mechanism differs from opioids, which act on the central nervous system, and seeks to offer pain relief without the addiction risks commonly associated with opioid analgesics.
Acute pain — a short-term sensation typically arising from injury or surgical trauma — is a common clinical challenge. Current treatments often include analgesics with or without opioids, and the FDA has increasingly promoted development of non-opioid pain options as part of its broader strategy to address pain management and reduce opioid reliance.
In clinical evaluation, the effectiveness of Journavx was established through two randomized, double-blind, placebo- and active-controlled trials involving adult surgical patients. One study followed abdominoplasty and the other bunionectomy procedures, with both trials showing a statistically significant reduction in pain for participants receiving Journavx compared to placebo. Participants with inadequate pain relief during the studies were permitted to use ibuprofen as rescue medication.
The safety profile of Journavx was assessed in 874 participants across these controlled surgical pain trials, with supplemental data from an additional 256 participants in an open-label study encompassing a range of acute pain conditions. Common adverse reactions included itching, muscle spasms, elevated creatine phosphokinase levels, and rash. The drug is contraindicated with strong CYP3A inhibitors, and patients are advised to avoid grapefruit products while taking Journavx.
The FDA granted the application several expedited designations — Breakthrough Therapy, Fast Track, and Priority Review — underscoring the agency’s emphasis on accelerating development of safe and effective alternatives to opioids. The approval was awarded to Vertex Pharmaceuticals Incorporated, the developer of Journavx.
Source credit:
- U.S. Food and Drug Administration. (2025, January 30). FDA approves novel non-opioid treatment for moderate to severe acute pain. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
